Rubius Therapeutics initiated with an Outperform at Leerink. Leerink analyst Jonathan Chang started Rubius Therapeutics with an Outperform rating and $30 price target as he has a positive long-term view on the stock. While the analyst acknowledges that any valuation method has significant shortcomings at this early stage, he believes that Rubius is “a swing for the fences type of play” with an approach that is uniquely differentiated and could be potentially transformative for the cell therapy field, if successful. Additionally, he views it as well positioned to execute on its strategy with a highly experienced management team and strong financial position.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.